Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Evening Speakeasy ~ busy work week now bleeding into the weekend.
Didn't trade anything this week. Sitting mostly liquid. Could have played $CEP quick but missed it.
$CMGO
$SEEK
Got ya $SEEK
$GLTV - Recent News Releases:
GLTV News: Greenlite Announces Changes to Carbon Offsets Marketing Website 09/06/2012 10:51:00 AM
GLTV News: Greenlite Announces Appointment of Bryan G. Crane 04/05/2012 09:00:00 AM
GLTV News: Greenlite Announces Letter of Intent for Reverse Merger With German-Based Member of Carbon Credit Exchanges 03/28/2012 09:00:00 AM
GLTV News: Greenlite Commences Carbon Offset Marketing to Online Community 03/12/2012 09:00:00 AM
HPTX. financial results for the second quarter of 2012.
http://finance.yahoo.com/news/hyperion-therapeutics-announces-second-quarter-200500687.html
The company reported cash and cash equivalents of $7.3 million as of June 30, 2012. Subsequent to the end of the quarter, on July 31, 2012, the company successfully closed its initial public offering and the underwriters exercised their over-allotment option in full raising proceeds, net of underwriter discounts, of $53.5 million. The company intends to use the proceeds primarily for the potential launch of its first drug, Ravicti(TM) (glycerol phenylbutyrate).
According to Chief Executive Officer, Donald J. Santel, "Having a completed IPO makes us well positioned for the potential approval and launch of Ravicti. We believe Ravicti offers meaningful benefits over the only product currently FDA-approved for the treatment of the most prevalent urea cycle disorders, or UCD. With the Prescription Drug User Fee Act (PDUFA) target action decision date on the New Drug Application for Ravicti now January 23, 2013, we are actively planning for launch, and are looking forward to bringing this important potential new drug to the UCD community."
Research and development expenses for the quarter ended June 30, 2012 were $2.7 million, compared to $4.6 million for the quarter ended June 30, 2011. The decrease was primarily due to reduced clinical development and consulting costs related to the company's hepatic encephalopathy (HE) Phase II trial which was largely enrolled in the fourth quarter of 2011 and completion of the long term safety extension trial in adults with UCD which occurred in 2011.
General and administrative expenses for the quarter ended June 30, 2012 were $1.5 million, compared to $2.5 million for the quarter ended June 30, 2011. The decrease was primarily due to decreases in professional and consulting fees related to a planned financing in 2011 as well as certain non-recurring legal expenses incurred in 2011.
Selling and marketing expenses for the quarter ended June 30, 2012 were $0.6 million, compared to $0.2 million for the quarter ended June 30, 2011. The increase was primarily due to increases in consulting fees and personnel costs as we prepare for the potential commercialization of Ravicti in UCD.
COO. financial results for the fiscal third quarter ended July 31, 2012.
http://finance.yahoo.com/news/cooper-companies-announces-third-quarter-200100660.html
Revenue increased 8% year-over-year to $378.2 million. CooperVision (CVI) revenue up 5% to $314.2 million and CooperSurgical (CSI) revenue up 20% to $64.0 million.
GAAP earnings per share (EPS) $1.36, up 46 cents or 51% from last year's third quarter.
Non-GAAP EPS $1.45, up 30 cents from last year's third quarter. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.
Free cash flow $62.9 million.
Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I'm very proud of the progress we made this quarter. We continued to execute on our long-range objectives with CooperVision gaining market share and CooperSurgical posting another strong quarter. We also closed on the acquisition of Origio, the leading global in-vitro fertilization (IVF) medical device company. Our business continues to perform well and we remain optimistic about continuing to deliver strong results."
Third Quarter GAAP Operating Highlights
Revenue $378.2 million, 8% above third quarter 2011, 9% excluding currency and acquisitions.
Gross margin 63% compared with 58% in last year's third quarter. The improvement was the result of improved margins at both CooperVision and CooperSurgical, and the $14.2 million Avaira(R) recall reserve for inventory and return provisions in last year's third quarter.
Operating margin 20% compared with 15% in last year's third quarter. The improvement was primarily the result of gross margin improvements.
Depreciation $21.9 million, up 10% from last year's third quarter. Amortization $5.9 million, up 7% from last year's third quarter primarily related to additional amortization from the acquisition of Origio.
Total debt increased $160.8 million from April 30, 2012, to $480.1 million due mainly to the Origio acquisition. Interest expense was $2.3 million compared with $3.2 million in last year's third quarter. Excluding a $0.4 million gain associated with the Origio acquisition, interest expense would have been $2.7 million.
Cash provided by operations $78.1 million, capital expenditures $24.1 million, insurance recovery $1.9 million and excluding Origio related costs of $7.0 million, free cash flow $62.9 million.
GILD chart.
iHub. http://ih.advfn.com/p.php?pid=squote&symbol=gild
[img]stockcharts.com/c-sc/sc?s=GILD&p=W&yr=1&mn=0&dy=0&i=t85240283495&r=1346958122209
[/img]
StocksDiva Bio/PR updates.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79279058
Baxter International Inc. (NYSE: BAX ) announced the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.
The candidate is a fully-human, recombinant anti-MIF (anti-macrophage migration inhibitory factor) monoclonal antibody with potential to be a new therapeutic agent in treatment of cancer. Monoclonal antibodies target a specific antigen in the body rather than traditional, systemic regimens. The anti-MIF antibody targets the MIF protein, a protein that induces inflammatory responses in the body and that has also been shown to influence the growth and spread of tumors. By inhibiting the cancer-promoting effects of MIF, the anti-MIF antibody may be capable of restricting the growth of tumors.
Targacept (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, announced it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB). Based on TC-5214's unique pharmacokinetic profile, an analysis of data from a completed clinical program and findings from additional preclinical studies, the company plans to initiate a Phase 2b study of TC-5214 in the first half of 2013.
“Current treatments for OAB have efficacy and tolerability shortcomings that limit their utility for many patients. The extensive renal excretion of TC-5214 suggests that a low dose of the drug should produce high bladder concentrations that could diminish sensations of urgency and be well tolerated,” said Michael Chancellor, M.D., Professor, Oakland University, William Beaumont School of Medicine and Chairman of the Urology Department at Beaumont Hospital. “Development of an oral drug with targeted effects at nicotinic receptors located in the bladder would represent a welcomed advance towards a potential new treatment paradigm for patients with OAB.”
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP).
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Morgan Stanley Global Healthcare Conference in New York City at 9:45 a.m. Eastern time on Wednesday, September 12, 2012.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.
Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has accepted for consideration additional data in the form of an appendix to Alimera's comments on the preliminary Appraisal Consultation Document (ACD) previously issued by NICE for the ILUVIEN®Single Technology Appraisal (STA).
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).
Array BioPharma Inc. (NASDAQ: ARRY) announced that Francis Bullock, Ph.D., and Kevin Koch, Ph.D., have decided not to stand for reelection to its Board of Directors and that David Snitman, Ph.D., intends to resign from the Board of Directors.
Baxter International Inc. (NYSE: BAX) previously announced that it will host its 2012 Investor Conference on Tuesday, October 9, 2012 at the Ritz-Carlton Hotel in Chicago, IL, from 8:00 a.m. until approximately 3:30 p.m. CT.
Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Morgan Stanley Global Health Care Conference on Monday, September 10, 2012, in New York.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it is seeking nominations for its Science Education Leadership Award program, which honors innovative science teachers in middle and high schools throughout New England.
Cytomedix, Inc. (OTCQB: CMXI), a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, today announced that the Company's AutoloGel™ System will be highlighted in an oral abstract and a poster presentation at the 4th Congress of the World Union of Wound Healing Societies (WUWHS 2012) being held from September 2-6, in Yokohama, Japan.
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to modulate the immune system, reduce severe inflammation, and mitigate organ failure caused by life-threatening illnesses, announced that Dr. Phillip Chan, Chief Executive Officer, will present at the 14th Annual Healthcare Conference at the Rodman & Renshaw Global Investment Conference.
Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, bio-based chemical and biopharmaceutical industries, announced today that its research and development center in the Netherlands is a participant in the HealthBread Project, a new multidisciplinary research program that has been awarded approximately one million Euro from the European Community's Seventh Framework Programme (FP7).
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that it has amended the Company’s Loan and Security Agreement with MidCap Financial, LLC ("MidCap" or the “Lender”) effective August 27, 2012.
Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that as of October 1, 2012, its corporate offices will be moved to Atlanta, Georgia, while maintaining a laboratory-based effort in the Boston area.
GenSpera, Inc. (OTCBB:GNSZ) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from Baird’s 2012 Healthcare Conference in New York.
Idera Pharmaceuticals, (NASDAQ: IDRA) a biotechnology company developing Toll-like receptor candidates for the treatment of autoimmune diseases and for use as vaccine adjuvants, today announced that members of the management team will be presenting at the Rodman & Renshaw Annual Global Investment Conference taking place at the Waldorf Astoria in New York City.
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) signed a contract with strategic partners in Bulgaria to register a company called Immunotech Laboratories B.G. LLC. Immunotech Laboratories, Inc. will own 34% of the Bulgarian subsidiary.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the following upcoming conferences: Rodman & Renshaw Annual Global Investment Conference – New York City, September 10, 2012, at 4:55 p.m. ET.
InSite Vision Incorporated (OTCBB: INSV) today introduced DuraSite 2®, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that it expects to submit its Biologic License Application (BLA) for Natpara™ (recombinant human parathyroid hormone (rhPTH [1-84])) in mid-2013.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Stifel Nicolaus Annual Healthcare Conference in Boston on Thursday, September 6, 2012 at 8:35 a.m. ET.
OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse and NeoPulse technologies to treat solid tumor cancers, received a new Method of Use and Device patent (Patent Application No. 200780014313.0, "Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection") for the OncoSec Medical System (OMS) electroporation device platform from the State Intellectual Property Office of the People's Republic of China.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR).
Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal year and fourth quarter ended June 30, 2012.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today provided an update on its strategic business goals for 2012.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it will be hosting Investor Day 2012 at The Yale Club of New York City on Tuesday, October 9, 2012.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that five presentations describing the investigation of methylnaltrexone bromide as a potential treatment for opioid-induced constipation in adult patients with chronic, non-cancer pain will occur during The National Conference on Pain for Frontline Practitioners, or “PAINWeek”.
Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) has received regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.
Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure.
SpectraScience, Inc. (OTCQB: SCIE) (PINKSHEETS: SCIE), a San Diego-based medical device company, today announced it has successfully completed installation and training for the WavSTAT4 Optical Biopsy System with PENTAX Europe at multiple customer sites, including the United Kingdom (London), France (Paris and Nantes), The Netherlands (Maastricht and Breda), and Germany (Erlangen).
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced that they have entered into an agreement to use OMT’s OmniRat™ to develop therapeutic antibody candidates for commercialization by WuXi’s global customers.
Zalicus Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.
about your last PM to me:
I've send that info to SG directly because the iHUB board mods always ignore it
Sorry board peeps - I got another big project for a major client that's, of course, do tomorrow.
Busy Busy
Hopefully everyone understands
What I really hope is that those that read the board have been reading between the lines.
Here's a hint, if you followed closely and actually paid attention you can say trade everyday. I refuse to spoon feed buy and sell pps. If u don't know why or think I should.......lmao u shouldn't be trading :p
Thanks to all the members and contributors!!!! I sincerely appreciate.
Great news - I believe there was a heads up on this board ;)
Always appreciated friend.
$ENTB wow big news! Entest BioMedical's ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous... http://finance.yahoo.com/news/entest-biomedicals-imenvax-tm-cancer-130000330.html
Very interesting reading available at the Medbox board. Worth a quick read.
Long story short there was a hostile low ball take over attempt. Company saw it and terminated the negotiations and relationship.
$MDBX
Good Morning Speakeasy ~ busy day yesterday. Hoping it calms down a bit today & tomorrow
SPA. Sparton Corporation Reports 43% Increase in Adjusted EPS to $0.40 for Fiscal 2012 Fourth Quarter; Operating Margin for Fourth Quarter Increases to 10%; 2012 Full Year Revenues Increase 10%
http://finance.yahoo.com/news/sparton-corporation-reports-43-increase-200500275.html
IMRS. IMRIS Announces Allowance of US Patent in MR Guided Radiation Therapy And First Product Clearance in Their Image Guided Radiation Therapy Business
http://finance.yahoo.com/news/imris-announces-allowance-us-patent-150000764.html
i was wondering about nokia - was wathcing for a little while
Looking(hard) for Nokia's bottom. NOK.
Great new phones coming out, but at date later this year.
Windows comes out OCT 26th.
Nokia Introduces Two Models of Windows Phone 8 Devices
http://ih.advfn.com/p.php?pid=nmona&article=54056402
$NBRI..Buying opportunity for cheap shares quickly comming to an end! Newest Raven Gold and Monte Cristo JV added to Frazier River JV and Ruby Mine aquisition pushes longer term FMV closer to $1.00 a share!>>>>>>> http://www.northbayresources.com/
PFE. FDA Approves Bosulif
FDA Approves Bosulif for Chronic Myelogenous Leukemia
http://www.drugs.com/newdrugs/fda-approves-bosulif-chronic-myelogenous-leukemia-3478.html
PCYC. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
http://finance.yahoo.com/news/pharmacyclics-reports-fourth-quarter-full-103000011.html
SUNNYVALE, Calif., Sept. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (PCYC) today reported financial results and recent developments for its fiscal year and fourth quarter ended June 30, 2012.
Financial Results for Fiscal Year and Fourth Quarter Ended June 30, 2012
The non-GAAP (Generally Accepted Accounting Principles) net income reported for the fiscal year ended June 30, 2012 was $21.9 million, or $0.32 and $0.30 per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $28.0 million, or $0.47 loss per share, for the fiscal year ended June 30, 2011. For the quarter ended June 30, 2012, the non-GAAP net loss was $15.1 million, or $0.22 loss per share, which compares with a non-GAAP net loss of $9.1 million, or $0.15 loss per share for the 2011 quarter. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.
The GAAP net income for the fiscal year ended June 30, 2012 was $12.0 million, or $0.17 per basic and diluted earnings per share. This compares with a GAAP net loss of $35.2 million, or $0.59 loss per share for the year ended June 30, 2011. For the quarter ended June 30, 2012, the GAAP net loss was $16.9 million, or $0.24 loss per share. This compares with a GAAP net loss of $11.0 million, or $0.18 loss per share for the fiscal quarter ended June 30, 2011.
Revenue for the fiscal year ended June 30, 2012 was $82.0 million, compared to $8.2 million for the fiscal year ended June 30, 2011, an increase of $73.8 million. Revenue for the quarter ended June 30, 2012 was $2.1 million, compared to $1.4 million for the quarter ended June 30, 2011, an increase of $0.7 million.
At June 30, 2012, the Company had cash, cash equivalents and marketable securities of $203.6 million, which compares with $112.3 million at June 30, 2011. Additionally, the Company had $5.8 million due from Janssen Biotech, Inc. at June 30, 2012 in connection with its cost sharing arrangement. As announced on August 1, 2012 and August 20, 2012, we triggered two milestone payment obligations of $50 million each from Janssen under the collaboration and license agreement.
"Since partnering with Janssen in December of last year, we have made good progress, clinically and organizationally. As reported, we initiated the first set of Phase III trials for ibrutinib (32765) and continue to broadly and quickly develop this compound across a variety of B-cell malignancies. Importantly, we continue to attract and hire highly competent professionals with excellent track records in the disciplines of science and administration from within the healthcare field. Our Executive Team is pleased with our progress and we thank each of our hard working employees for their dedication and continued commitment to truly make a significant difference for the betterment of healthcare patients in need," said Bob Duggan, Chairman & CEO of Pharmacyclics.
OREX. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
http://finance.yahoo.com/news/orexigen-therapeutics-announces-continued-rapid-103000810.html
PCRX. Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy
Results from Pooled Analysis of More than 900 Patients Published Online in Current Medical Research and Opinion
http://finance.yahoo.com/news/reduced-pain-opioid-opioid-related-103000225.html
PSTI. Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Patient With Blood Cancer, Acute Myeloid Leukemia, Experienced Improved Clinical Condition and Released From Hadassah Hospital
http://finance.yahoo.com/news/third-critically-ill-patient-successfully-090000175.html
Good Morning Speakeasy ~
HRC. Hill-Rom Announces Fourth Quarter 2012 Dividend
BATESVILLE, Ind., Sept. 4, 2012 /PRNewswire/ -- Hill-Rom Holdings, Inc. (HRC) announced today that its board of directors has declared a fiscal year 2012 fourth quarter dividend of $0.125 per share. This dividend is payable on September 28, 2012 to shareholders of record as of the close of business on September 14, 2012.
http://finance.yahoo.com/news/hill-rom-announces-fourth-quarter-210000602.html
GRFS - that's a great chart. The stock is up over 100% from its Pre-run "dip"
$GRFS
Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
http://finance.yahoo.com/news/intercept-pharmaceuticals-files-registration-statement-200100407.html
S-1 9/4/12
http://www.sec.gov/Archives/edgar/data/1270073/000114420412049445/v321826_s1.htm
GRFS. Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
Awards fund early-career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency
http://finance.yahoo.com/news/grifols-awards-winners-9th-annual-164400326.html
Just a little quiet reflection at that holy place lol..
Its funny, im literally standing in front of the New York Stock excange on wall street today and i am yet to make a single trade today lmao
$ENTB..From Pastor Phil!>>>> http://www.entb.net/imagelib/pdf/entbFactssheet20110628.pdf
RENU big news premarket, they have completed the aquisition of Team energy
RenuEn Corporation Completes Acquisition of Team Energy, Inc.
PrintAlert
RenuEn Corporation (OTCBB: RENU), a rapidly expanding renewable energy roll-up company focused on solar, wind and geothermal energy solutions, today announced that the Company's acquisition of Team Energy, Inc. has been finalized. The most immediate corporate change for RenuEn is the appointment of new CEO and Chairman of the Board, Mr. Don Wood of Team Energy.
James Scott, current CEO of RenuEn, said, "I am very pleased to complete this major strategic acquisition, and to announce Mr. Wood as our new CEO and Chairman. He has a proven record as a leader in the industry, and has assembled a world-class team of Energy Project experts. I will still be very involved with the Company's operations, specifically with the legislative prerogatives. The Landfill Compressed Natural Gas (CNG) business is primarily with municipalities, and this aspect of our business is integral to the success of obtaining such projects."
The terms of the acquisition were the issuance of 200 million shares of RenuEn common stock to Team Energy. Also, one preferred share will be issued to Team Energy, which will consist of a 50.1% voting right. This share is not convertible into common, nor will it be listed or traded separately. There was no cash remuneration.
"There will be other positive developments in the near future, such as getting our consolidated financial statements brought up-to-date and ultimately filed with OTC Markets so that the Company's reporting status will be upgraded to current," Mr. Scott went on to say. "We are very focused on providing transparency within our company, which in tandem with Mr. Wood's industry expertise is precisely what RenuEn needs to enhance our presence within the investment and alternative energy communities. With the current projects that we are working on, we feel that we will be an attractive prospect for institutional investors, which means that we are committed to providing clear and concise disclosures of our operations and financials."
Don Wood, incoming CEO of RenuEn, commented on the acquisition closing by saying, "We are excited to get this transaction closed so that we can focus on executing our business plan. With James' political expertise and our project experience, I feel that we are in a great position to reward our shareholders. I look forward to providing the Company with the leadership it deserves; and in keeping with our goal of full transparency, look forward to keeping our valued shareholders informed of the progress of the multiple exciting projects that we are working on."
About RenuEn Corporation
RenuEn Corporation focuses on Geothermal, Wind and Solar Energy Systems sales and installation for the residential, commercial and governmental market place enhanced with a keen eye toward Economic Think Tank Participation specific to the Renewable Energy Industry. Our goal is to be the premier gateway to the renewable energy market for both technology developers and consumer solutions while providing leadership to an expansive and rapidly growing yet simultaneously fragile industry. For more information regarding RenuEn Corporation, please visit: www.renuen.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact and Inquiries for Investor Relations:
Michael Irving
Paramount Advisors, LLC
407-878-5462
mike@parvise.com
MYL. Mylan Selected as a Leading ARV Supplier to India's National AIDS Control Organization
http://finance.yahoo.com/news/mylan-selected-leading-arv-supplier-113000644.html
ANSS. ANSYS Launches Student Version of Robust Simulation Technology
Academic Student Now Available for Purchase in the U.S.
http://finance.yahoo.com/news/ansys-launches-student-version-robust-112500182.html
NPSP. Revestive® (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)
SBS is a rare and highly disabling condition that impacts patients’ quality of life and can lead to serious life-threatening complications
Teduglutide has received orphan drug designation for the treatment of SBS from the European Medicines Agency (EMA) and U.S. Food and Drug Administration
http://finance.yahoo.com/news/revestive-teduglutide-receives-european-marketing-110000940.html
PFE. Pfizer Receives EU Marketing Authorization for INLYTA® (Axitinib)
Approved for the treatment of adult patients with advanced renal cell carcinoma after failure of prior treatment with SUTENT® (sunitinib) or a cytokine
http://finance.yahoo.com/news/pfizer-receives-eu-marketing-authorization-100000369.html
GE. GE Healthcare Launches Modular Biopharmaceutical Factory, KUBio
Innovative approach will save biopharmaceutical manufacturers time and money.
http://finance.yahoo.com/news/ge-healthcare-launches-modular-biopharmaceutical-083000481.html
$CFGX and $RENU on close watch this week.
Good Morning Speakeasy ~ Early start for me today.
Looks like market open will be lunch time for me lol :p
$CMGO
$SEEK
GWTR - Great post!!! Always appreciate the beefy DD :)
QMCI follow-up. SC-13G filed recently. Colin Gilbert, Trustee for the CMG Family Irrevocable Trust is now the proud owner of 5,364,000 common shares which is 6% of the O/S.
IMO and FWIW.
QMCI DD POST
QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, TMX Group, Dow Jones & Company, Sungard, Wells Fargo, U.S. Bank, Penson Worldwide, Broadridge Financial Systems, Ridge Clearing, Regal Securities, Jitney Trade, Southwest Securities, Zecco Trading, Zacks Investment Research, General Electric, Dow Chemical, Bombardier, Business Wire, Marketwire, FolioFN, Captivate Network, ChoiceTrade, Qtrade Financial, CNW Group, TradeFreedom, Gain Securities, Gmarkets, Questrade, Schaeffer's Investment Research, Answers.com, WebFinance, and others.
Real time level II used by the professionals.
Streaming data on your computer or mobile device.
Learn more about Quotemedia's real time level II and streaming market data or try it free for seven days.
Click here or here to view demos and review product offerings.
Share Structure
Authorized common Shares 150,000,000
Outstanding and Issued 89,371,320
Authorized preferred shares 10,000,000
Outstanding and issued preferred shares 0
Click here to visit the Quotemedia message board here on investorshub.
All information in this post is IMO and FWIW.
GWTR DD POST <<updated.>>
Global Water Technologies, Inc.
351 W. 10th Street #537
Indianapolis, Indiana 46202
Phone: 317-452-4488
Fax: 317-452-4489
www.gwtr.com
Share Structure
Authorized Shares 1,000,000,000
Outstanding shares 11,448,605
Float 5,895,503
Company Subsidiary
Electric H2O, Inc. is a subsidiary of Global Water Technologies that utilizes non-chemical water treatment to prevent scaling in cooling towers through its line of ED2000™ ED2000PLUS™ and AquaPhysic™ systems. Developed through research at Drexel University, the three proprietary technologies address scale, microbiological growth, corrosion and fouling in cooling water systems.
Click here to learn more about Electric H20 products and history.
Intellectual Property
Global Water Technologies has a small patent portfolio that includes U.S. Patent No. 5,951,856 for Water Hardness Reduction through Interactive Molecular Agitation and Filtration. The patent was issued in 1999 and the 12-year maintenance fee has been paid. On January 11, 2011, the company was issued U.S. Patent No. 7,867,470 for the On-Site Manufacture of Sulfuric Acid.
Click here to learn more about on-site manufacturing of sulfuric acid
Click here to learn more about water hardness reduction.
Company Affiliations & Partnerships
Global Water Technologies, Inc. has developed a number of strategic partnerships with related companies, academic institutions and other organizations that seek to improve water efficiency.
The company is an affiliate of the Indiana University Research and Technology Corporation through its Emerging Technologies Center in downtown Indianapolis.
Click here to learn more about IURTC
Global Water plans to work on further development and commercialization with Agua Dulce, a world leader in alkaline water and soil treatment. Agua Dulce is an innovative company that uses sulfurous acid to treat water for agriculture, industry and other specialized uses.
Click here to learn more about AguaDulce
Global Water Technologies (OTC Pink: GWTR) is pleased to announce that its new partnership with Martinek Water Management, GmbH, is moving forward with efforts to set up a pilot project in the United States to provide real-time monitoring of leak conditions and reduce loss in drinking water systems.
Click here to learn more about Martinek Water Management
The company is also pleased to be part of a new water technology cluster formed in the Indiana-Ohio-Kentucky region and the national Water Innovations Alliance.
Click here to learn more about the Water Innovations Alliance.
In March 2011 the United States EPA had a presentation at the Water Innovations Alliance.
http://www.waterinnovations.org/PDF/Therouxpresentation3-8-11MT.pdf
all of which?
The Speakeasy Bin stocks are the stocks on my radar that i trade in, out and around of. I try to keep picks that will allow my money to be fluid but at the same time give me the ability to jump in play and out of plays continuously.
Followers
|
64
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5074
|
Created
|
12/30/11
|
Type
|
Free
|
Moderator qwertytrader | |||
Assistants mick ontopofit fast.money |
Posts Today
|
0
|
Posts (Total)
|
5074
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |